Biotech & Medicine
133 articles RSS
FDA Approves Xocova as First Oral COVID-19 Post-Exposure Prevention Drug, Based on Phase 3 Trial Showing 67% Risk Reduction
The FDA has approved Shionogi's ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19, the first oral antiviral cleared for that indication in the US.
Replimune's Oncolytic Virus Achieves 47.8% Three-Year Survival in Checkpoint-Resistant Melanoma as Company Lines Up Third FDA Submission
IGNYTE trial data show 83.5% of responders alive at three years; Replimune plans third BLA resubmission after two FDA rejections.
FDA Approves Decnupaz, the First CD123-Targeting ADC for a Blood Cancer With Historically Dismal Prognosis
AbbVie's pivekimab sunirine-pvzy wins FDA approval for BPDCN on May 27, with a 69.7% complete remission rate in newly diagnosed patients and the first-ever outpatient initiation for this ultra-rare malignancy.
FDA Approves First All-Oral AML Regimen as Inqovi Plus Venetoclax Clears for Patients Ineligible for Intensive Chemotherapy
The FDA on May 13 cleared Taiho Oncology's Inqovi combined with venetoclax as the first fully oral treatment for older or unfit AML patients, replacing injection-based clinic visits.
Lilly's VERVE-102 Base Editor Cuts LDL Cholesterol by 62% in Phase 1b Trial, Results Published in NEJM
A single infusion of VERVE-102 reduced LDL-C by up to 62% and PCSK9 by up to 88% in a 35-patient trial, with effects sustained up to 18 months.
Scribe Therapeutics Wins TGA Clearance to Begin First Human Trial of STX-1150, a CRISPR Epigenetic Therapy Targeting PCSK9
Scribe's ELXR platform silences PCSK9 in the liver without cutting DNA; a single low dose sustained LDL reductions for roughly 18 months in primates.
US Measles Cases Hit 1,952 as Country Edges Toward Losing Elimination Status It Has Held Since 2000
The CDC logged 1,952 measles cases through May 21, 2026 — on pace to surpass last year's high not seen since 1992 — as a Lancet study concludes four of seven elimination indicators have already been missed.
Lilly Acquires Engage Bio for Up to $202 Million to Build Non-Viral DNA Delivery Platform
Eli Lilly acquired Engage Bio and its Tethosome non-viral DNA delivery platform for up to $202 million, aiming to overcome the immune and redosing limits of viral gene therapies.
WHO Declares Bundibugyo Ebola Outbreak in DRC and Uganda a Public Health Emergency of International Concern
A rare Bundibugyo virus outbreak with no licensed vaccines or treatments has been declared a PHEIC, with over 650 suspected cases and 160 suspected deaths across three DRC provinces and Uganda.
Siemens Healthineers Wins FDA 510(k) Clearance for Six AI-Powered Artis Interventional Imaging Systems With Optiq Deep-Learning Chain
Six Artis interventional imaging platforms with the Optiq AI deep-learning imaging chain cleared by FDA on May 12, six months after RSNA 2025 debut.
Max Planck Team Maps Cell-Surface Sugar Code at Nanometre Resolution, Revealing Cancer and Immune Signatures
Scientists have developed Glycan Atlasing, a super-resolution technique that reads shifting sugar patterns on cell surfaces to distinguish cancer stages from healthy tissue and activated from resting immune cells.
FDA Approves First ctDNA-Guided Adjuvant Immunotherapy for Bladder Cancer, Rewriting the Post-Surgery Treatment Playbook
Atezolizumab becomes the first therapy cleared for use only in patients whose blood tests reveal molecular residual disease after bladder removal surgery.